» Articles » PMID: 29895722

Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD)

Overview
Journal Toxins (Basel)
Publisher MDPI
Specialty Toxicology
Date 2018 Jun 14
PMID 29895722
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The uremic syndrome, which is the clinical expression of chronic kidney disease (CKD), is a complex amalgam of accelerated aging and organ dysfunctions, whereby cardio-vascular disease plays a capital role. In this narrative review, we offer a summary of the current conservative (medical) treatment options for cardio-vascular and overall morbidity and mortality risk in CKD. Since the progression of CKD is also associated with a higher cardio-vascular risk, we summarize the interventions that may prevent the progression of CKD as well. We pay attention to established therapies, as well as to novel promising options. Approaches that have been considered are not limited to pharmacological approaches but take into account lifestyle measures and diet as well. We took as many randomized controlled hard endpoint outcome trials as possible into account, although observational studies and post hoc analyses were included where appropriate. We also considered health economic aspects. Based on this information, we constructed comprehensive tables summarizing the available therapeutic options and the number and kind of studies (controlled or not, contradictory outcomes or not) with regard to each approach. Our review underscores the scarcity of well-designed large controlled trials in CKD. Nevertheless, based on the controlled and observational data, a therapeutic algorithm can be developed for this complex and multifactorial condition. It is likely that interventions should be aimed at targeting several modifiable factors simultaneously.

Citing Articles

Future of Uremic Toxin Management.

Vanholder R, Snauwaert E, Verbeke F, Glorieux G Toxins (Basel). 2024; 16(11).

PMID: 39591217 PMC: 11598275. DOI: 10.3390/toxins16110463.


Inflammation and all-cause mortality in patients undergoing peritoneal dialysis.

Oliveira Junior W, Giarola L, Ferreira L, Schettini I, Turani S, Oliveira A Einstein (Sao Paulo). 2024; 22:eAO0627.

PMID: 39140572 PMC: 11323835. DOI: 10.31744/einstein_journal/2024AO0627.


Indoxyl Sulfate-Induced Macrophage Toxicity and Therapeutic Strategies in Uremic Atherosclerosis.

Wakamatsu T, Yamamoto S, Yoshida S, Narita I Toxins (Basel). 2024; 16(6).

PMID: 38922148 PMC: 11209365. DOI: 10.3390/toxins16060254.


Effects of Dietary Intervention on Nutritional Status in Elderly Individuals with Chronic Kidney Disease.

Cacciapuoti N, Lonardo M, Di Lauro M, Di Lorenzo M, Aurino L, Pacella D Nutrients. 2024; 16(5).

PMID: 38474760 PMC: 10934554. DOI: 10.3390/nu16050632.


The Human Microbiome in Chronic Kidney Disease: A Double-Edged Sword.

Wehedy E, Shatat I, Al Khodor S Front Med (Lausanne). 2022; 8:790783.

PMID: 35111779 PMC: 8801809. DOI: 10.3389/fmed.2021.790783.


References
1.
Xia J, Wang L, Ma Z, Zhong L, Wang Y, Gao Y . Cigarette smoking and chronic kidney disease in the general population: a systematic review and meta-analysis of prospective cohort studies. Nephrol Dial Transplant. 2017; 32(3):475-487. DOI: 10.1093/ndt/gfw452. View

2.
Jamison R, Hartigan P, Kaufman J, Goldfarb D, Warren S, Guarino P . Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA. 2007; 298(10):1163-70. DOI: 10.1001/jama.298.10.1163. View

3.
Watson M, Baker T, Nguyen A, Sebastianelli M, Stewart H, Oliver D . Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: a retrospective cohort study. Am J Kidney Dis. 2012; 60(3):409-16. DOI: 10.1053/j.ajkd.2012.04.023. View

4.
Crowley M, Diamantidis C, McDuffie J, Cameron C, Stanifer J, Mock C . Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. Ann Intern Med. 2017; 166(3):191-200. PMC: 5293600. DOI: 10.7326/M16-1901. View

5.
Elliot S, Karl M, Berho M, Xia X, Pereria-Simon S, Espinosa-Heidmann D . Smoking induces glomerulosclerosis in aging estrogen-deficient mice through cross-talk between TGF-beta1 and IGF-I signaling pathways. J Am Soc Nephrol. 2006; 17(12):3315-24. DOI: 10.1681/ASN.2006070799. View